Loading clinical trials...
Loading clinical trials...
A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Nivolumab
Gemcitabine
+7 more
Locations
12
United States
Ucla
Los Angeles, California, United States
Yale University
New Haven, Connecticut, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Memorial Sloan Kettering Nassau
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Start Date
December 16, 2011
Primary Completion Date
July 20, 2016
Completion Date
July 23, 2021
Last Updated
October 12, 2021
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
NCT05005403
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions